James W Murrough

List of Publications by Year
in descending order

151 papers	14,732 citations	25034 57 h-index	20358 116 g-index
162 all docs	162 docs citations	162 times ranked	13592 citing authors

#	Article	IF	Citations
1	Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial. American Journal of Psychiatry, 2013, 170, 1134-1142.	7.2	965
2	Neurobiology of resilience. Nature Neuroscience, 2012, 15, 1475-1484.	14.8	934
3	Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression. Biological Psychiatry, 2013, 74, 250-256.	1.3	632
4	Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression. Biological Psychiatry, 2010, 67, 139-145.	1.3	589
5	Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16136-16141.	7.1	545
6	The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. American Journal of Psychiatry, 2018, 175, 150-158.	7.2	476
7	Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder. JAMA Psychiatry, 2014, 71, 681.	11.0	466
8	Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. Lancet, The, 2017, 389, 834-845.	13.7	442
9	Lack of Ventral Striatal Response to Positive Stimuli in Depressed Versus Normal Subjects. American Journal of Psychiatry, 2006, 163, 1784-1790.	7.2	424
10	A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. American Journal of Psychiatry, 2016, 173, 816-826.	7.2	388
11	A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder. Biological Psychiatry, 2014, 76, 970-976.	1.3	369
12	Targeting glutamate signalling in depression: progress and prospects. Nature Reviews Drug Discovery, 2017, 16, 472-486.	46.4	345
13	EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION. Depression and Anxiety, 2014, 31, 335-343.	4.1	275
14	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. American Journal of Psychiatry, 2021, 178, 383-399.	7.2	270
15	Cognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies. Neurobiology of Learning and Memory, 2011, 96, 553-563.	1.9	264
16	Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychological Medicine, 2015, 45, 3571-3580.	4.5	244
17	Ketamine Treatment and Global Brain Connectivity in Major Depression. Neuropsychopharmacology, 2017, 42, 1210-1219.	5.4	240
18	Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. International Journal of Neuropsychopharmacology, 2010, 13, 71-82.	2.1	239

#	Article	IF	Citations
19	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular Psychiatry, 2020, 25, 1592-1603.	7.9	235
20	Amino Acid Neurotransmitters Assessed by Proton Magnetic Resonance Spectroscopy: Relationship to Treatment Resistance in Major Depressive Disorder. Biological Psychiatry, 2009, 65, 792-800.	1.3	227
21	A Functional Magnetic Resonance Imaging Study of Deliberate Emotion Regulation in Resilience and Posttraumatic Stress Disorder. Biological Psychiatry, 2009, 66, 656-664.	1.3	209
22	ECT in Treatment-Resistant Depression. American Journal of Psychiatry, 2012, 169, 1238-1244.	7.2	208
23	Ketamine for Treatment-Resistant Unipolar Depression. CNS Drugs, 2012, 26, 189-204.	5.9	203
24	Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. International Journal of Neuropsychopharmacology, 2014, 17, 331-336.	2.1	195
25	Screening and Management of Depression in Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2019, 73, 1827-1845.	2.8	182
26	Ketamine Safety and Tolerability in Clinical Trials for Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2015, 76, 247-252.	2.2	179
27	Neurobiology of Resilience: Interface Between Mind and Body. Biological Psychiatry, 2019, 86, 410-420.	1.3	175
28	Ketamine as a Novel Antidepressant: From Synapse to Behavior. Clinical Pharmacology and Therapeutics, 2012, 91, 303-309.	4.7	147
29	Attention Bias Variability and Symptoms of Posttraumatic Stress Disorder. Journal of Traumatic Stress, 2014, 27, 232-239.	1.8	145
30	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers in Psychiatry, 2020, 11, 595584.	2.6	143
31	Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Translational Psychiatry, 2017, 7, e1065-e1065.	4.8	135
32	Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR in Biomedicine, 2012, 25, 1073-1087.	2.8	134
33	A randomized proof-of-mechanism trial applying the â€˜fast-failâ€™ approach to evaluating Î¹-opioid antagonism as a treatment for anhedonia. Nature Medicine, 2020, 26, 760-768.	30.7	129
34	Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. Australian and New Zealand Journal of Psychiatry, 2020, 54, 29-45.	2.3	126
35	Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. Human Brain Mapping, 2016, 37, 3214-3223.	3.6	125
36	A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. American Journal of Psychiatry, 2021, 178, 193-202.	7.2	122

#	Article	IF	Citations
37	Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. Psychopharmacology, 2011, 213, 547-553.	3.1	118
38	Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial. Neuropsychopharmacology, 2015, 40, 1084-1090.	5.4	117
39	KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. Nature Communications, 2016, 7, 11671.	12.8	109
40	Shared Neural Phenotypes for Mood and Anxiety Disorders. JAMA Psychiatry, 2020, 77, 172.	11.0	106
41	Emerging drugs for the treatment of anxiety. Expert Opinion on Emerging Drugs, 2015, 20, 393-406.	2.4	102
42	Ketamine for treatment-resistant depression: recent developments and clinical applications: TableÂ1. Evidence-Based Mental Health, 2016, 19, 35-38.	4.5	102
43	Acetyl- <scp>l</scp> -carnitine deficiency in patients with major depressive disorder. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 8627-8632.	7.1	102
44	The role of the locus coeruleus in the generation of pathological anxiety. Brain and Neuroscience Advances, 2020, 4, 239821282093032.	3.4	102
45	Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. Translational Psychiatry, 2015, 5, e509-e509.	4.8	93
46	Moral distress in frontline healthcare workers in the initial epicenter of the COVIDâ€19 pandemic in the United States: Relationship to PTSD symptoms, burnout, and psychosocial functioning. Depression and Anxiety, 2021, 38, 1007-1017.	4.1	86
47	The Effect of Early Trauma Exposure on Serotonin Type 1B Receptor Expression Revealed by Reduced Selective Radioligand Binding. Archives of General Psychiatry, 2011, 68, 892.	12.3	84
48	Reduced Amygdala Serotonin Transporter Binding in Posttraumatic Stress Disorder. Biological Psychiatry, 2011, 70, 1033-1038.	1.3	79
49	Pharmacological Treatments for Patients with Treatment-Resistant Depression. Pharmaceuticals, 2020, 13, 116.	3.8	78
50	Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatric Disease and Treatment, 2013, 9, 1101.	2.2	76
51	Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology, 2014, 231, 481-488.	3.1	73
52	Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. Neuropsychopharmacology, 2020, 45, 975-981.	5.4	71
53	Efficacy of Esketamine Augmentation in Major Depressive Disorder. Journal of Clinical Psychiatry, 2020, 81, .	2.2	71
54	The promise of ketamine for treatmentâ€resistant depression: current evidence and future directions. Annals of the New York Academy of Sciences, 2015, 1345, 47-58.	3.8	70

#	Article	IF	Citations
55	Increased ventricular lactate in chronic fatigue syndrome measured by ¹H MRS imaging at 3.0 T. II: comparison with major depressive disorder. NMR in Biomedicine, 2010, 23, 643-650.	2.8	68
56	Psychological Impact of the COVID-19 Pandemic on Frontline Health Care Workers During the Pandemic Surge in New York City. Chronic Stress, 2021, 5, 247054702097789.	3.4	65
57	Neural correlates of interoception: Effects of interoceptive focus and relationship to dimensional measures of body awareness. Human Brain Mapping, 2017, 38, 6068-6082.	3.6	63
58	Neuropeptide Y, resilience, and PTSD therapeutics. Neuroscience Letters, 2017, 649, 164-169.	2.1	62
59	Neural correlates of rumination in major depressive disorder: A brain network analysis. NeuroImage: Clinical, 2020, 25, 102142.	2.7	62
60	Is There Anything Really Novel on the Antidepressant Horizon?. Current Psychiatry Reports, 2012, 14, 643-649.	4.5	59
61	Cerebellar Morphology and the Effects of Stimulant Medications in Youths with Attention Deficit-Hyperactivity Disorder. Neuropsychopharmacology, 2014, 39, 718-726.	5.4	59
62	Insulin receptor substrate in brain-enriched exosomes in subjects with major depression: on the path of creation of biosignatures of central insulin resistance. Molecular Psychiatry, 2021, 26, 5140-5149.	7.9	59
63	COGNITIVE-EMOTIONAL TRAINING AS AN INTERVENTION FOR MAJOR DEPRESSIVE DISORDER. Depression and Anxiety, 2014, 31, 699-706.	4.1	58
64	A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder. International Journal of Neuropsychopharmacology, 2018, 21, 3-11.	2.1	56
65	Positron Emission Tomography Shows Elevated Cannabinoid <scp>CB</scp>₁ Receptor Binding in Men with Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2012, 36, 2104-2109.	2.4	53
66	The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nature Reviews Drug Discovery, 2019, 18, 82-84.	46.4	52
67	Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology, 2020, 45, 1656-1663.	5.4	50
68	In vivo 1H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. Neuroscience Letters, 2014, 569, 74-79.	2.1	45
69	A selective neurokinin-1 receptor antagonist in chronic PTSD: A randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology, 2011, 21, 221-229.	0.7	44
70	Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial. Journal of Affective Disorders, 2017, 218, 277-283.	4.1	41
71	Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. Molecular Psychiatry, 2020, 25, 1323-1333.	7.9	40
72	Cortical abnormalities and association with symptom dimensions across the depressive spectrum. Journal of Affective Disorders, 2016, 190, 529-536.	4.1	38

#	Article	IF	Citations
73	Ultra-high field MRI reveals mood-related circuit disturbances in depression: a comparison between 3-Tesla and 7-Tesla. Translational Psychiatry, 2019, 9, 94.	4.8	37
74	A Case of Sustained Remission Following an Acute Course of Ketamine in Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2011, 72, 414-415.	2.2	37
75	A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. Journal of Affective Disorders, 2018, 230, 56-64.	4.1	36
76	Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology, 2019, 44, 1233-1238.	5.4	35
77	ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. Contemporary Clinical Trials, 2019, 77, 19-26.	1.8	34
78	Ketamine-induced changes in plasma brain-derived neurotrophic factor (BDNF) levels are associated with the resting-state functional connectivity of the prefrontal cortex. World Journal of Biological Psychiatry, 2020, 21, 696-710.	2.6	34
79	Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. American Journal of Psychiatry, 2021, 178, 437-446.	7.2	33
80	Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. Neuropsychopharmacology, 2019, 44, 1812-1819.	5.4	32
81	Cracking the moody brain: Lifting the mood with ketamine. Nature Medicine, 2010, 16, 1384-1385.	30.7	31
82	Determinants and Predictive Value of Clinician Assessment of Shortâ€Term Suicide Risk. Suicide and Life-Threatening Behavior, 2019, 49, 614-626.	1.9	30
83	Development of the Ketamine Side Effect Tool (KSET). Journal of Affective Disorders, 2020, 266, 615-620.	4.1	28
84	Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. International Journal of Neuropsychopharmacology, 2021, 24, 383-391.	2.1	28
85	Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedonia. Translational Psychiatry, 2021, 11, 565.	4.8	27
86	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Translational Psychiatry, 2018, 8, 280.	4.8	26
87	Sub-millimeter variation in human locus coeruleus is associated with dimensional measures of psychopathology: An in vivoÂultra-high field 7-Tesla MRI study. NeuroImage: Clinical, 2020, 25, 102148.	2.7	25
88	A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder. International Journal of Neuropsychopharmacology, 2020, 23, 783-790.	2.1	23
89	Association Between Depression and Severity of Dry Eye Symptoms, Signs, and Inflammatory Markers in the DREAM Study. JAMA Ophthalmology, 2022, 140, 392.	2.5	22
90	Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimulation, 2018, 11, 75-84.	1.6	20

#	Article	IF	Citations
91	Effects of chronic physical disease and systemic inflammation on suicide risk in patients with depression: a hospital-based caseâ€“control study. Psychological Medicine, 2020, 50, 29-37.	4.5	20
92	A prospective cohort study of the psychological consequences of the COVID-19 pandemic on frontline healthcare workers in New York City. International Archives of Occupational and Environmental Health, 2022, 95, 1279-1291.	2.3	20
93	The Serotonin Transporter and Emotionality: Risk, Resilience, and New Therapeutic Opportunities. Biological Psychiatry, 2011, 69, 510-512.	1.3	19
94	High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. Neuropsychopharmacology, 2019, 44, 390-398.	5.4	19
95	Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. Neuropsychopharmacology, 2021, 46, 2266-2277.	5.4	19
96	Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders. Current Behavioral Neuroscience Reports, 2015, 2, 216-225.	1.3	18
97	Beyond the neuron: Role of non-neuronal cells in stress disorders. Neuron, 2022, 110, 1116-1138.	8.1	18
98	Ketamine for Depression: An Update. Biological Psychiatry, 2016, 80, 416-418.	1.3	17
99	The Neurobiology of Resilience: Complexity and Hope. Biological Psychiatry, 2019, 86, 406-409.	1.3	17
100	A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression. Npj Digital Medicine, 2018, 1, .	10.9	16
101	Vortioxetine Versus Placebo for Major Depressive Disorder. Journal of Clinical Psychiatry, 2021, 82, .	2.2	16
102	The Serotonin 1B Receptor: A New Target for Depression Therapeutics?. Biological Psychiatry, 2011, 69, 714-715.	1.3	15
103	Transdiagnostic Psychiatric Symptoms, Burnout, and Functioning in Frontline Health Care Workers Responding to the COVID-19 Pandemic. Journal of Clinical Psychiatry, 2021, 82, .	2.2	15
104	Factors Associated With Longitudinal Psychological and Physiological Stress in Health Care Workers During the COVID-19 Pandemic: Observational Study Using Apple Watch Data. Journal of Medical Internet Research, 2021, 23, e31295.	4.3	15
105	Hippocampal subfield-specific connectivity findings in major depressive disorder: A 7 Tesla diffusion MRI study. Journal of Psychiatric Research, 2019, 111, 186-192.	3.1	14
106	Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression. Translational Psychiatry, 2022, 12, 12.	4.8	14
107	Advances in Psychopharmacology for Anxiety Disorders. Focus (American Psychiatric Publishing), 2014, 12, 152-162.	0.8	13
108	Corticotropin-Releasing Factor Type 1 Receptor Antagonists for Stress-Related Disorders: TimeÂto Call It Quits?. Biological Psychiatry, 2017, 82, 858-860.	1.3	13

#	Article	IF	Citations
109	Prazosin during threat discrimination boosts memory of the safe stimulus. Learning and Memory, 2017, 24, 597-601.	1.3	12
110	The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants. CNS Drugs, 2022, 36, 207-216.	5.9	12
111	Altered hippocampus and amygdala subregion connectome hierarchy in major depressive disorder. Translational Psychiatry, 2022, 12, 209.	4.8	12
112	Analysis of Clinical Trial Exit Interview Data in Patients with Treatment-Resistant Depression. Patient, 2019, 12, 527-537.	2.7	9
113	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Focus (American) Tj ETQq1 1 0.784314 rgBT /Overlo	0.8	9
114	Depletion of brain norepinephrine does not reduce spontaneous ambulatory activity of rats in the home cage. Brain Research, 2000, 883, 125-130.	2.2	8
115	Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence. Advances in Pharmacology, 2020, 89, 163-194.	2.0	8
116	Exaggerated amygdala response to threat and association with immune hyperactivity in depression. Brain, Behavior, and Immunity, 2022, 104, 205-212.	4.1	7
117	Reply to: Dose- and Exposure-Response to Ketamine in Depression. Biological Psychiatry, 2011, 70, e11-e12.	1.3	6
118	Ketamine for Posttraumatic Stress Disorderâ€"Reply. JAMA Psychiatry, 2015, 72, 95.	11.0	6
119	Dissociating self-generated volition from externally-generated motivation. PLoS ONE, 2020, 15, e0232949.	2.5	6
120	Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date. Drug Design, Development and Therapy, 2021, Volume 15, 151-157.	4.3	6
121	Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHVâ€5500) in PTSD: A randomized, doubleâ€blind, placeboâ€controlled trial. Depression and Anxiety, 2021, 38, 1108-1119.	4.1	6
122	â€œDoes Ketamine Have Rapid Anti-Suicidal Ideation Effects?â€• Current Treatment Options in Psychiatry, 2015, 2, 383-393.	1.9	5
123	Protein Biomarkers in Major Depressive Disorder: An Update. Advances in Experimental Medicine and Biology, 2019, 1140, 585-600.	1.6	5
124	The Implications of Neurocognitive Deficits in Posttraumatic Stress Disorder. Psychiatric Annals, 2011, 41, 408-412.	0.1	4
125	Pharmacological Treatments for Anhedonia. Current Topics in Behavioral Neurosciences, 2022, , 467-489.	1.7	4
126	F124. Mapping the Neural Correlates of Mood and Anxiety Disorders Onto Research Domain Criteria: A Meta-Analysis of 226 Task-Related Functional Imaging Studies. Biological Psychiatry, 2019, 85, S261.	1.3	3

#	Article	IF	Citations
127	Effects of Sleep, Exercise, and Leadership Support on Resilience in Frontline Healthcare Workers During the COVID-19 Pandemic. Journal of Occupational and Environmental Medicine, 2021, Publish Ahead of Print, .	1.7	3
128	Current Treatments for Anxiety and Obsessive-Compulsive Disorders. Current Treatment Options in Psychiatry, 2014, 1, 248-262.	1.9	2
129	Initial Evidence for Brain Plasticity Following a Digital Therapeutic Intervention for Depression. Chronic Stress, 2019, 3, 247054701987788.	3.4	2
130	Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial. Journal of Psychopharmacology, 2021, 35, 124-127.	4.0	2
131	Intrasubject functional connectivity related to selfâ€generated thoughts. Brain and Behavior, 2021, 11, e01860.	2.2	2
132	Overcoming Antidepressant Treatment Resistance: Focus on Glutamate. Modern Problems of Pharmacopsychiatry, 2010, , 89-100.	2.5	1
133	Glutamate NMDA receptor modulators for the treatment of depression: trials and tribulations. Psychopharmacology, 2015, 232, 1497-1499.	3.1	1
134	Ketamineâ€™s Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies. , 2016, , 99-121.		1
135	171. A Randomized Controlled Dose-Ranging Study of Intranasal Administration of Neuropeptide Y in Patients with Posttraumatic Stress Disorder. Biological Psychiatry, 2017, 81, S71.	1.3	1
136	Psychopharmacology and Experimental Therapeutics for Bipolar Depression. Focus (American) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382	0.8	1
137	Chemical, Manufacturing, and Standardization Controls of Grape Polyphenol Dietary Supplements in Support of a Clinical Study: Mass Uniformity, Polyphenol Dosage, and Profiles. Frontiers in Nutrition, 2021, 8, 780226.	3.7	1
138	CHAPTER 9. Neurocircuitry of Anxiety Disorders: Focus on Panic Disorder and Post-traumatic Stress Disorder. RSC Drug Discovery Series, 2012, , 226-257.	0.3	0
139	871. Modulation of the Insula and Somatosensory Cortex by Ondansetron. Biological Psychiatry, 2017, 81, S352.	1.3	0
140	T131. KNCQ Channel Opener Ezogabine_x000B_as a Treatment for Depression: A Preliminary Resting State fMRI Analysis. Biological Psychiatry, 2018, 83, S179.	1.3	0
141	86. Role of the Epigenetic Agent Acetyl-L-Carnitine as Gating Biomarker in Depression and Influences of Childhood Trauma. Biological Psychiatry, 2018, 83, S35-S36.	1.3	0
142	F142. Effect of Treatment Resistance Status on Whole Brain Voxel-Based Morphometry in Major Depressive Disorder. Biological Psychiatry, 2018, 83, S293.	1.3	0
143	F163. Inflammation is Associated With Mesolimbic Reward Circuitry in Major Depression. Biological Psychiatry, 2018, 83, S302.	1.3	0
144	T129. Brain Connectivity Changes Associated With a Cognitive-Emotional Training Intervention for Depression. Biological Psychiatry, 2018, 83, S178.	1.3	0

#	Article	IF	Citations
145	65. From Stress Resilience to Novel Therapeutics: KCNQ Channel Openers and Other Approaches Emerging From Translational Neuroscience. Biological Psychiatry, 2018, 83, S27.	1.3	0
146	116. Results of the NIMH FAST-MAS Phase IIa Proof of Mechanism Study of the Effects of the Selective Î¹ÂOpioid Antagonist JNJ-67953964 on fMRI Ventral Striatal Activity in Anhedonic Patients. Biological Psychiatry, 2019, 85, S48-S49.	1.3	0
147	132. Structural and Connectomic Brain Features of Treatment Resistant Depression and Antidepressant Response to Ketamine. Biological Psychiatry, 2019, 85, S55.	1.3	0
148	S8. Increased Locus Coeruleus Volume in Humans With Pathological Anxiety: An Ultra-High Field 7-Tesla MRI Study. Biological Psychiatry, 2019, 85, S299-S300.	1.3	0
149	Editorial: Pharmacotherapy of Anxiety Disorders: Promises and Pitfalls. Frontiers in Psychiatry, 2021, 12, 662963.	2.6	0
150	New Mechanisms, New Opportunities. Journal of Clinical Psychiatry, 2019, 80, .	2.2	0
151	The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry. Journal of Affective Disorders, 2022, , .	4.1	0